Checkpoint Therapeutics, Inc.
CKPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41 | $103 | $192 | $268 |
| % Growth | -60.2% | -46.4% | -28.4% | – |
| Cost of Goods Sold | $0 | $43,566 | $49,825 | $48,453 |
| Gross Profit | $41 | -$43,463 | -$49,633 | -$48,185 |
| % Margin | 100% | -42,197.1% | -25,850.5% | -17,979.5% |
| R&D Expenses | $36,152 | $43,566 | $49,825 | $48,453 |
| G&A Expenses | $20,063 | $8,685 | $8,300 | $8,538 |
| SG&A Expenses | $20,063 | $8,685 | $8,700 | $8,538 |
| Sales & Mktg Exp. | $0 | $0 | $400 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $56,215 | $52,251 | $58,525 | $56,991 |
| Operating Income | -$56,174 | -$52,148 | -$58,333 | -$56,723 |
| % Margin | -137,009.8% | -50,629.1% | -30,381.8% | -21,165.3% |
| Other Income/Exp. Net | -$66 | $301 | -$4,291 | $53 |
| Pre-Tax Income | -$56,240 | -$51,847 | -$62,624 | -$56,670 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$56,240 | -$51,847 | -$62,624 | -$56,617 |
| % Margin | -137,170.7% | -50,336.9% | -32,616.7% | -21,125.7% |
| EPS | -1.42 | -2.77 | -7.09 | -7.45 |
| % Growth | 48.7% | 60.9% | 4.8% | – |
| EPS Diluted | -1.42 | -2.77 | -7.09 | -7.45 |
| Weighted Avg Shares Out | 39,674 | 18,742 | 8,836 | 7,603 |
| Weighted Avg Shares Out Dil | 39,674 | 18,742 | 8,836 | 7,603 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $84 | $160 | $53 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $4,451 | $237 |
| EBITDA | -$56,174 | -$52,148 | -$53,882 | -$56,486 |
| % Margin | -137,009.8% | -50,629.1% | -28,063.5% | -21,077% |